Location: Boston, MA
CIK: 0001637359 · Show all filings
Period: Q2 2016 (← Previous) (Next →)
Filing Date: Aug 3, 2016
Total Value: $135M (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | Juno Therapeutics | 1,229,512 | $47.26M | 35.1% | $52.22 | — | Common Stock | 48205A109 |
| — | Paratek Pharmaceuticals | 2,600,410 | $36.17M | 26.8% | $34.18 | — | Common Stock | 699374302 |
| — | Egalet | 2,889,926 | $14.33M | 10.6% | $5.98 | — | Common Stock | 28226B104 |
| — | FibroGen | 822,175 | $13.49M | 10.0% | $27.34 | — | Common Stock | 31572Q808 |
| — | Nabriva Therapeutics | 1,145,890 | $8.594M | 6.4% | $9.50 | — | Sponsored ADR | 62957M104 |
| — | ESSA Pharma | 1,696,969 | $5.006M | 3.7% | $5.22 | — | Common Stock | 29668H104 |
| — | Pieris Pharmaceuticals | 2,262,832 | $3.643M | 2.7% | $1.83 | — | Common Stock | 720795103 |
| EDIT | Editas Medicine | 105,008 | $2.562M | 1.9% | $26.29 | +28.3% | Common Stock | 28106W103 |
| — | Proteon Therapeutics | 250,000 | $2.008M | 1.5% | $10.40 | — | Common Stock | 74371L109 |
| — | CymaBay Therapeutics | 606,100 | $1.055M | 0.8% | $1.94 | — | Common Stock | 23257D103 |
| — | Dicerna Pharmaceuticals | 223,457 | $670K | 0.5% | $16.47 | — | Common Stock | 253031108 |